|
What
students say about our program faculty... |
|
| |
Sessions I & II – The Product Development
Process
Guest Lecturers at Stony Brook University & Stony Brook
Manhattan
- Magdy Abdel-Malik, Ph.D., President, Quaestio Global Partners LLC
- Gretchen Argast, Ph.D., Senior Research Scientist, Cancer Biology, OSI Pharmaceuticals, Inc.
- Karim Berrada, Ph.D., Director, Drug Discovery Group, inGenious Targeting Laboratory, Inc.
- Michael Boisclair, Ph.D., Director, Leads Discovery, OSI Pharmaceuticals, Inc.
- Elizabeth Buck, Ph.D., Senior Research Scientist, Department of Translational Research, OSI Pharmaceuticals, Inc.
- Lee Chen, Director of Marketing, Vitatex, inc.
- Yogita Desai, Ph.D., Assistant Director of Chemical Manufacturing Control, Forest Laboratories, Inc.
- Javan Esfandiari, Ph.D., Vice President, Research and Development, Chembio Diagnostic Systems, Inc.
- Andrew Garton, Ph.D., Senior Research Investigator, OSI Pharmaceuticals, Inc.
- Ron Guido, Director & Global Regulatory Lead, Pfizer, Inc.
- Michael Hadjiagyrou, Ph.D., Associate Professor, Department of Biomedical Engineering, Stony Brook University
- John Haley, Ph.D., Senior Director, Molecular Biology, OSI Pharmaceuticals, Inc.
- Imran Haque, M.B.A., Director, Business Technology, Pfizer, Inc.
- Qun-Sheng Ji, Senior Research Investigator of Cancer Biology, OSI Pharmaceuticals, Inc.
- Jon Klein, Vice President, AGI Dermatics
- Sharon Klugewicz, Sr. Vice President, Global Quality Operations, Pall Life Sciences
- King Lee, Ph.D., R.A.C., Vice President of Clinical & Regulatory Affairs, Cornerstone Pharmaceuticals
- Alan McEmber, RAC, Director, Worldwide Regulatory Strategy, Pfizer, Inc.
- Jules Mitchel, MBA, Ph.D., President, Target Health, Inc.
- Kevin Murphy, Ph.D., Clinical Director of Psychiatry, Pfizer, Inc.
- Glenn Neuman, New World Regulatory Solutions
- Srinivas Pentyala, Ph.D., Associate Professor & Director of Translational Research, Department of Anesthesiology, Stony Brook University
- Sue Poirier, Pfizer, Inc.
- Joseph Scaduto, Executive Director, Long Island Life Sciences Initiative
- Nelson Scharadin, MS, Founder, BioNano Systems, Inc.
- Salam Shabaan, Ph.D., OSI Pharmaceuticals, Inc.
- Paul Sheiffele, Director, Business Development, inGenious Targeting Laboratory, Inc.
- A. Laurie Shroyer, Ph.D., M.S., Professor of Preventive Medicine, Division of Evaluative Sciences, Stony Brook University Medical Center
- Les Stutzman, Chembio Diagnostic Systems, Inc.
- Natalya Valiero, Senior Consultant, MDI Consultants, Inc.
Session III - The Business of Bioscience
Stony Brook University Guest Lecturers
- Michael Bielski, J.D., Assistant Director, Science & Technology Commercialization, Center for Biotechnology
- Edward Caffrey, President, Icon Clinical Laboratories
- Paul Esatto, Partner, Scully Scott Murphy & Presser PC
- Lorrence Green, Ph.D., President, Westbury Diagnostics
- James Hayward, Former CEO of the Collaborative Group and a founding member of NYBA
- John A. Hill, Business Facilitator, John A. Hill & Associates, Inc.
- Gabe Leung, Vice President Commercial Operations, OSI Pharmaceuticals, Inc.
- Bill Liggan, Director, Human Resources, ICON Central Laboratories
- Bob Rodriguez, BSc, MBA, CEO and Executive Vice-President of Business Development, Cornerstone Pharmaceuticals
- Barbara Sawitsky, MBA, CLP, Director, Patents and Licensing/Business Development, NY Blood Center and Lindsley F. Kimball Research Institute
- Larry Siebert, President, ChemBio Diagnostic Systems, Inc.
- Ken Sonnenfeld, Ph.D., Esq., Partner, King & Spalding LLP
- Darshan Wariabharaj, Manager, Regulatory Affairs, OSI Pharmaceuticals, Inc.
- Yongzhi (Mimi) Yang, Associate, Scully Scott Murphy & Presser PC
- Xiaochun Zhu, Ph.D., Partner, Scully Scott Murphy & Presser PC
Stony Brook Manhattan Guest Lecturers
- Jason Alter, Ph.D., Director of Marketing, Aureon Laboratories
- Jeff Aibel, IMS Health
- Brian Buxton, Principal, Easton Associates
- Safi Bahcall, Ph.D., CEO, Synta Pharmaceuticals
- Alain Cappeluti, Vice President, Financial Operations, CoGeneSys
- Mark Carvlin, Partner, SWGC Life Sciences
- Joseph Ceccoli, Former Chief Operating Officer, The Collaborative Group, Ltd.
- Ron Cohen, MD, President and CEO, Acorda Therapeutics
- Tim Cooke, Ph.D., MBA, CEO, Mojave Therapeutics.
- Paul Esatto, Scully Scott Murphy & Presser PC
- Christopher Fenimore, Manager of Finance, Regeneron Pharmaceuticals, Inc.
- Allen Goldberg, Managing Partner, The Channel Group
- Paul Harney, Principal, Swiftwater Group
- Sandra P. Kim, Ph.D., Patent Department, Pfizer, Inc.
- Peter Ludwig, MS, JD, LLM, Patent Attorney, Partner, Darby and Darby
- Fred Price, Former CEO, BioMarin Pharmaceuticals
- Dennis Purcell, Senior Managing Director, Perseus Soros Biopharmaceutical Fund
- Barbara Sawitsky, MBA, CLP, Director, Patents and Licensing/Business Development, NY Blood Center and Lindsley F. Kimball Research Institute
- Bob Schaffer, JD, Patent Attorney, Partner, Darby and Darby
- Nelson Scharadin, Founder, BioNano Systems, Inc.
- Ken Sonnenfeld, Ph.D., Esq., Partner, King & Spalding LLP
- Dave Sudolsky, MBA, Principal of Sudco Consulting, former president and CEO of Arizeke Pharmaceuticals.
- Robert Sullivan, JD, Patent Attorney, Partner, Darby and Darby
- Harri Taranto, Managing Director, Symphony Capital LLC
back to top
|
|
|
 |
|
Director
CBT
Chair BME Dept.
|
| >
Clint Rubin, StonyBrook |
|
| "To be competitive in
industry, biosciences graduates must understand the intricate
process of translating basic research into innovative, market
driven products. Further, these graduates must be able to navigate
the complex pathways of intellectual property management and
the regulatory affairs of agencies such as the FDA. There is
a critical need for programs that encourage life sciences students
to integrate industry-relevant training and experience with
their basic science education." |
|
 |
| > Program Development |
|
 |
| > Continued Support |
|
  |
|
|
|
 |
|
